Explore our ACCC 2020 Impact Report, the Oncology Issues, Vol.36, N.4, and our video podcast, CANCER BUZZ TV.

St. Luke's Cancer Institute


St. Luke's Cancer Institute
Boise, Idaho

Improve Oral Oncolytic Workflow and Reduce Treatment Delays with a Pharmacist Collaborative Practice Agreement

Learn how a pharmacy resident project supported the creation and implementation of an oral oncolytic collaborative practice agreement (CPA) that expanded pharmacist scope of practice, decreased turnaround time for processing prescriptions, improved provider satisfaction, and decreased patient prescription costs. Today, St. Luke's Cancer Institute’s CPA allows pharmacists to sign prescriptions on behalf of providers for interventions such as renal or hepatic dose adjustments, dose rounding, renewal of prescription refills, adjustment for toxicities, dosing based on appropriate indication, and the ordering of laboratory tests and/or exams.

To hear this ACCC Innovator Award session on-demand, please visit the ACCC eLearning portal.

Watch Video

Read Blog

Pharmacists Expand Role in Collaborative Practice Agreement

innovatorAwards-2020-sealSingular-80x80To speed approvals for recommended medication adjustments to oral oncolytic prescriptions, St. Luke's Cancer Institute created a pilot program to test the efficacy of a collaborative practice agreement (CPA) between the institute’s medical oncologists and oncology pharmacists. Within two months, St. Luke’s found that while it took an average of seven minutes for the pilot group to turn around one medication adjustment, it took 3,311 minutes for the group that had to wait for physician approval. Two months into the pilot, St. Luke’s approved the CPA for site-wide implementation.”
Read Full Story